Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irosustat in Early ER+ Breast Cancer (IPET)
NCT01662726Phase 2Terminated
- Sponsor
- Imperial College London
- Start
- Aug 2012
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irosustat in breast cancer, sponsored by Imperial College London. Primary endpoint: Changes in [18F] fluorothymidine (FLT) uptake at 2 weeks. Started Aug 2012; status: terminated.
02
Drugs
irosustat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01662726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01662726.